Barnaby Hunt - Concepedia

Author

Barnaby Hunt

Novo Nordisk (Denmark)ORCID

Also Known As

B Hunt, B. Hunt, BARNABY HUNT, Barnaby Hunt, Hunt B, Hunt, Barnaby

127

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (Denmark)Novo Nordisk (United Kingdom)Novo Nordisk (United States)Complejo Hospitalario Torrecárdenas Örebro University

About

Barnaby Hunt is an author at Novo Nordisk (Denmark) specializing in medicine, pharmacotherapy, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	76
2	Diabetes	3	3	53
3	Health Sciences	2	2	29
4	Pharmacology	2	2	38
5	Health Policy	1	1	15

Barnaby Hunt

Publications

Citations

H-Index

Page 1

	Year	Citations
Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis Johan Jendle, Åsa Ericsson, Jens Gundgaard, Diabetes Therapy	2020	62
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme Stephen C. Bain, Brian Bekker Hansen, Samuel J. P. Malkin, Diabetes Therapy	2019	50
Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK Stephen C. Bain, Brian Bekker Hansen, Barnaby Hunt, Journal of Medical Economics	2019	48
Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK Adie Viljoen, C. S. Hoxer, Pierre Johansen, Diabetes Obesity and Metabolism	2018	44
Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States J Langer, Barnaby Hunt, William J. Valentine Journal of Managed Care Pharmacy	2013	40
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands Barnaby Hunt, Samuel J. P. Malkin, Robert Gerald Jan Moes, BMJ Open Diabetes Research & Care	2019	40
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis B.B. Hansen, Solomon Nuhoho, Sarah Ali, Journal of Medical Economics	2020	34
Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden Åsa Ericsson, Richard F. Pollock, Barnaby Hunt, Journal of Medical Economics	2013	30
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting Peter Gæde, Pierre Johansen, Christian K. Tikkanen, Diabetes Therapy	2019	30
Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin Antonio Pérez, Pedro Mezquita Raya, Antonio Ramírez de Arellano, Diabetes Therapy	2015	29

Page 1